Navigation Links
DuraHeart(TM) LVAS Receives Conditional Approval for US Pivotal Trial
Date:3/3/2008

ANN ARBOR, Mich., March 3 /PRNewswire/ -- Terumo Heart, Inc. announced today that they have received conditional approval from the Food and Drug Administration (FDA) to begin enrollment in the US Pivotal Trial of the DuraHeart (TM) LVAS for a Bridge-to-Transplant (BTT) indication.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070227/CLTU043LOGO )

(Photo: http://www.newscom.com/cgi-bin/prnh/20080303/CLM012 )

Dr. David Munjal, Vice President of Clinical Studies, Regulatory Affairs and Quality Systems at Terumo Heart, Inc., commented: "We are extremely pleased that FDA has allowed us to move directly to the Pivotal Trial based on our existing European data. The conditional approval was granted pending answers to some additional questions. Terumo Heart, Inc. has already responded to the FDA concerning these questions and final approval is anticipated in the near future."

Dr. Chisato Nojiri, M.D., Ph.D., Chief Executive Officer for Terumo Heart, Inc., said: "The approval of the IDE Pivotal Trial is a major milestone for Terumo Heart and we are especially pleased that the FDA has also issued approval for patients to be discharged home. This positive decision by the FDA was based on our robust preclinical data and the successful European clinical trial of the DuraHeart System."

The Pivotal Trial will be a multi-center, prospective, non-randomized study of 140 patients and will include up to 40 centers. The Principal Investigators will be Francis Pagani, M.D., Ph.D., from the University of Michigan and Yoshifumi Naka, M.D., Ph.D., from Columbia Presbyterian Hospital in New York.

The DuraHeart LVAS is a third generation circulatory support device intended to provide cardiac support for patients who are at risk of death due to end-stage left ventricular failure. It is currently the only CE marked implantable LVAS combining a centrifugal pump with magnetic levitation of the impeller, providing exceptional reliability and minimizing the potential for blood damage and thrombus. The DuraHeart LVAS is not available for sale in the United States.

Terumo Heart, Inc. is a US subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products.

For more information, please contact Mark White, Marketing Manager, Terumo Heart, Inc. at (734) 741-6262 or mark.white@terumomedical.com.


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Terumo Heart Reports Summary of DuraHeart(TM) LVAS Clinical Trial Results
2. Terumo Heart to Announce Results of European Clinical Trial of DuraHeart(TM) LVAS at European Association of Cardiothoracic Surgeons Meeting in September
3. Vermillion Receives Award From the Society of Gynecologic Oncologists
4. Arbios Receives Conditional Approval from the FDA to Initiate Pivotal Clinical Trial for SEPET(TM)
5. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
6. Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency
7. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
8. Photo: Welchol(TM) (colesevelam HCl) Receives FDA Approval to Reduce Blood Glucose in Adults with Type 2 Diabetes
9. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
10. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
11. Vical Receives Payment from AnGes MG for Allovectin-7(R) Phase 3 Pivotal Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... Jan. 20, 2017 ARMO BioSciences, Inc., a ... on the Company,s lead investigational immuno-oncology drug AM0010 (PEGylated ... the American Society of Clinical Oncology (ASCO), taking place ... "AM0010 induces the expansion ... T cells in the blood and tumors of ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
(Date:1/20/2017)... -- Research and Markets has announced the addition ... BMP, BUN Creatinine, Electrolyte Testing, HbA1c Testing, Comprehensive Metabolic Panel, Liver ... - 2024" report to their offering. ... The global clinical laboratory testing market ... Introduction of innovative solutions on the grounds of maximum efficiency and ...
Breaking Medicine Technology:
(Date:1/22/2017)... ... 2017 , ... Medical lab testing through hospitals and other traditional ... test will take days to arrive to the end customer, having to travel through ... their lab tests, bypassing the cost and delay of traditional means. Now all employees ...
(Date:1/21/2017)... ... ... Seamild, the largest manufacturer of oats in China, is now aiming at global business ... recognized globally as one of the healthiest cereals, XieQingkui, the founder of Seamild, strongly ... to sow the seed of good karma. Buddhism spirit featuring benevolence and sacrifice are ...
(Date:1/21/2017)... ... January 21, 2017 , ... Santa Rosa Orthopaedics ... Petaluma, located at 167 Lynch Creek Way. The Petaluma office features three comfortable ... and rehabilitation services and on-site x-ray services. Two multi-specialist orthopaedic surgeons ...
(Date:1/20/2017)... ... January 20, 2017 , ... A new partnership between Goodwill® and ... longer use or need, from clothes to couches to dressers and bicycles. Roadie — ... them to the nearest Goodwill donation center through February 28th. , “January is ...
(Date:1/20/2017)... ... ... Bionic Sports Nutrition LLC, an American company devoted to developing high-quality nutritional supplements for ... Show in Hilton Head, SC. , Bionic Sports Nutrition manufactures its entire line ... all clients at reasonable prices. At the ECRM trade show, it had a unique ...
Breaking Medicine News(10 mins):